4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD

4D Molecular Therapeutics, Inc.

2024-Q1 EPS reported -$0.66 revenue$28,000

Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.
Cash $589M after $337M gross proceeds from upsized follow-on; runway into H1 2027.
4D-150 wet AMD: 89% injection burden reduction, 84% patients with 0-1 injections at 24 wks; Phase 3 start Q1 2025.
Upcoming: 4D-150 broader wet AMD data at ASRS July 2024; 4D-710 CF interim data at ECFS June 2024.
R&D expenses $27.9M, G&A $10.3M; both up YoY driven by clinical trial progression and headcount.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

4D Molecular Therapeutics, Inc. reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-057035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.